Simon Paul Watkins
22 Papers
32 Citations
Simon Paul Watkins is an academic researcher. The author has contributed to research in topics: Prostate cancer & Rucaparib. The author has an hindex of 7, co-authored 15 publications.
Chat about Author
Papers
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Martin Bambury,Eric Voog,Jingsong Zhang,Josep M. Piulats,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Celestia S. Higano,Laurence Eliot Miles Krieger,Cora N. Sternberg,Simon Paul Watkins,Darrin Despain,Andrew Simmons,Andrea Loehr,Melanie Dowson,Tony Golsorkhi,Simon Chowdhury,Simon Chowdhury +27 more
TL;DR: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
605
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim Abida,David Campbell,Akash Patnaik,Jeremy Shapiro,Brieuc Sautois,Nicholas J. Vogelzang,Eric Voog,Alan H. Bryce,Ray McDermott,Francesco Ricci,Julie Rowe,Jingsong Zhang,Josep M. Piulats,Karim Fizazi,Axel S. Merseburger,Celestia S. Higano,Laurence Eliot Miles Krieger,Charles J. Ryan,Felix Y. Feng,Andrew Simmons,Andrea Loehr,Darrin Despain,Melanie Dowson,Foad Green,Simon Paul Watkins,Tony Golsorkhi,Simon Chowdhury +26 more
TL;DR: In this prospective, genomics-driven study of rucaparib in mCRPC, limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2 are found, however, patients with alteration in other DDR-associated genes (e.g., PALB2) may benefit from ParP inhibition.
345
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Karim Fizazi,Josep M. Piulats,M. Neil Reaume,Peter Ostler,Ray McDermott,Joel Roger Gingerich,Elias Pintus,Srikala S. Sridhar,Richard Martin Bambury,Urban Emmenegger,Henriette Lindberg,David L. Morris,Franco Nolè,John Staffurth,Charles H. Redfern,María Isabel Sáez,Wassim Abida,Gedske Daugaard,Axel Heidenreich,Laurence Eliot Miles Krieger,Brieuc Sautois,Andrea Loehr,Darrin Despain,Catherine A Heyes,Simon Paul Watkins,Simon Chowdhury,Charles J. Ryan,Alan H. Bryce +27 more
TL;DR: In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), showed a high level of activity in patients who had metastatic, castration-resistant prostate cancer associated with a deleterious BRCA alteration as mentioned in this paper .
122
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Wassim Abida,David Campbell,Akash Patnaik,Alan H. Bryce,Jeremy Shapiro,Richard Martin Bambury,Jingdong Zhang,John M. Burke,Daniel Castellano,Albert Font,Vinod Ganju,Anne-Claire Hardy-Bessard,Ray McDermott,Brieuc Sautois,Dominique Spaeth,Eric Voog,Josep M. Piulats,Elias Pintus,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Andrea Loehr,Darrin Despain,Andrew Simmons,Melanie Dowson,Jowell Go,Simon Paul Watkins,Simon Chowdhury +29 more
TL;DR: TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA or other DNA damage repair (DDR) gene alteration as discussed by the authors .
42
Evaluation of absorption, distribution, metabolism, and excretion of [ 14 C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
Mingxiang Liao,Simon Paul Watkins,Eileen Nash,Jeff Isaacson,Jeff Etter,Jeri Beltman,Rong Fan,Li Shen,Abdul Mutlib,Vendel Kemeny,Zsuzsanna Papai,Pascal van Tilburg,Jim J. Xiao +12 more
TL;DR: The data suggest that rucaparib is eliminated through multiple pathways, including metabolism and renal and biliary excretion, as well as the presence of metabolites in plasma.